Member Info for RuckRover

Dragon,
Are you talking about financial results or Covidity trial start?

C7,
I would have taken up your bet but only just woke up!
As you know, I'm not committed to the "buy and hold" mantra, but now is not a time to be selling imo.

A "first patient dosed" does not require an RNS.
However, it is inconceivable to think it is not "newsworthy". If the BOD have a modicum of empathy for the long suffering shareholders they will issue one. Any news of progress, however small, would be most welcome.
I'm going for one tomorrow (again)

Chelsea,
"Anyone have any thoughts on this??"

Personally I'd be happy to hear of anyone getting any treatment anywhere using any delivery method. Maybe tomorrow?

Three actually!

Ah yes, "anticipation of news".
When you have been waiting for a bus a long time but one hasn't come, you expect a bus to arrive at anytime.

TF,
I think the statement it MUST be this week is more a plea than a forecast. A bit like a child on a long car journey, "we MUST be there by now"

Anyway, I'm going for an RNS tomorrow.

Well Tuesday is statistically the most likely for an RNS.
If we can get miavoce to dream of an Aldi prawn ring rather than a meat and tatty pie we'll be looking at 4 quid.

Ratty,
Lol.

Max,
"Ruck you and Mystic Meg need to spend less time together lol"

I am Mystic Meg, didn't you know?

Mia,
The diabetes is a deficiency, in the case of LD this was funding. She, along with the board, secured a custard tart amount from Vulpes. Then along came Redmile and offered something even more substantial- a meat and potato pie. Interesting, you consider Vulpes the establishment (co op) but Redmile a "street vendor". This possibly shows you have some underlying concerns about Redmile's motives.
The relative prices of tart v pie could be an indication of future share price hopes 36p - £1.45

AIMO.

LL,
Medicines don't work if they're kept in the cupboard!
Don't forget, the pipeline of drugs have come from the same lab, same team driven by the same desire and led by LD. If one works, the probability is they will all work.

So why have they cancelled?

They don't think we will need variant proof vaccines?
They don't think this one is going to get approval.
They are looking elsewhere?

Bunsie,
Good to hear from you, it's been a while.
I think we are long way from having to worry about corporation tax!

crumbs,
I'm sure she will. Anyone in the vicinity to check out the s****y restaurants in Nottingham?

LL,
Yesterday's RNS didn't come out until after 17:00

Morning C7,

I'd like to think we will get a mega RNS this morning to counteract yesterday's.
But how that wouldn't be deemed insider trading I don't know.
Well know soon!

Crumbs,
"here's a funny thing Modernas Mcap is $172 billion Mercks $190 billion...how can that even be!!
Ruck"

You have to factor PE into the equation (as I do). Merck's is 36, Moderna's is 49.
The historic average PE on the Various stock exchanges across all sectors has been between 15 and 20. A high PE comes in when future earnings are expected to rise, a low PE when future earnings are expected to fall. (Tesco is 3). A start up company with huge potential may have a PE in exces of 100. What you have to understand is that high PEs cannot be maintained indefinitely as the market becomes saturated. (Exponential growth cannot be maintained forever)

If you want to call the mathematical calculation "sentiment" that's fine by me! :)

Morning all,
Ivy,
" it is by nature fun to speculate about future multiples of the current SP as long as people don’t start confusing fantasy with reality and over extend themselves"

I don't have a problem exploring "what if" scenarios but it is important that people remember it is an IF.
Yesterday, the scenario was "what if MODI sales reached the same level as Keytruda - $25B?"
This gave rise to numerous valuations on SP. Actually, the formula used to calculate is very simple - it is the values you plug in that are the challenge. ALL companies are valued on earnings or estimated future earnings so the calculation is
Income (sales and royalties) * net profit * PE = Market cap / shares in issue = future SP.
So on sales of £18B ($25B), 15% royalty, 20% net profit, PE of 10 and 985M shares = SP of £5.52

If you go ultra optimistic you could say
Sales of £18B ($25B), 15% royalty, 60% net profit, PE of 40 and 985M shares = SP of £66.20

So the individual figures aren't unrealistic - there are companies who make 60% net and there are companies with PEs of 40 (and over). This would depend on the likely success and value of other products in the pipeline.
So two sets of figures with arguably realistic values but different by a factor of 10.
Note: All based on a highly speculative sales figure of $25B.

Ray,
"Surely mcap is the simple formula of
Share price x no of shares"

Simplistically yes. But there has to be some intrinsic supportable value underpinning it.
So in practice it s the value of the company divided by the number of shares that sets the sp.